| __timestamp | Axsome Therapeutics, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4279200 | 19586000 |
| Thursday, January 1, 2015 | 6776987 | 29135000 |
| Friday, January 1, 2016 | 21199860 | 42791000 |
| Sunday, January 1, 2017 | 19957616 | 49577000 |
| Monday, January 1, 2018 | 23495055 | 89209000 |
| Tuesday, January 1, 2019 | 53647067 | 69099000 |
| Wednesday, January 1, 2020 | 70244579 | 75961000 |
| Friday, January 1, 2021 | 58060725 | 90467000 |
| Saturday, January 1, 2022 | 57947447 | 74552000 |
| Sunday, January 1, 2023 | 97944000 | 91593000 |
Data in motion
In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Axsome Therapeutics, Inc. and Supernus Pharmaceuticals, Inc. have demonstrated significant commitment to R&D, as evidenced by their financial allocations. From 2014 to 2023, Axsome's R&D expenses surged by over 2,000%, reflecting a strategic focus on pioneering treatments. Meanwhile, Supernus maintained a steady investment, with a peak in 2021, underscoring its dedication to enhancing its product pipeline. Notably, in 2023, Axsome's R&D spending reached its zenith, surpassing Supernus by approximately 7%. This trend highlights the competitive nature of the industry, where companies strive to outpace each other in developing groundbreaking therapies. As we look to the future, these investments are poised to drive transformative advancements in patient care, setting the stage for the next wave of medical breakthroughs.
R&D Spending Showdown: Vertex Pharmaceuticals Incorporated vs Axsome Therapeutics, Inc.
Comparing Innovation Spending: argenx SE and Supernus Pharmaceuticals, Inc.
R&D Spending Showdown: United Therapeutics Corporation vs Axsome Therapeutics, Inc.
R&D Spending Showdown: Sarepta Therapeutics, Inc. vs Axsome Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Axsome Therapeutics, Inc. and PTC Therapeutics, Inc.
R&D Spending Showdown: Axsome Therapeutics, Inc. vs Agios Pharmaceuticals, Inc.
Axsome Therapeutics, Inc. or BioCryst Pharmaceuticals, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Axsome Therapeutics, Inc. vs Xencor, Inc.
Research and Development Investment: Axsome Therapeutics, Inc. vs Novavax, Inc.
Comparing Innovation Spending: ADMA Biologics, Inc. and Supernus Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: CymaBay Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.